These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 34659909)
1. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis. Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909 [TBL] [Abstract][Full Text] [Related]
2. Novel combination of imipridones and histone deacetylase inhibitors demonstrate cytotoxic effect through integrated stress response in pediatric solid tumors. Chang WI; Honeyman JN; Zhang J; Lin C; Sharma A; Zhou L; Oliveira J; Tapinos N; Lulla RR; Prabhu VV; El-Deiry WS Am J Cancer Res; 2023; 13(12):6241-6255. PubMed ID: 38187038 [TBL] [Abstract][Full Text] [Related]
3. Dopamine pre-treatment impairs the anti-cancer effect of integrated stress response- and TRAIL pathway-inducing ONC201, ONC206 and ONC212 imipridones in pancreatic, colorectal cancer but not DMG cells. Zhang Y; Tapinos N; Lulla R; El-Deiry WS Am J Cancer Res; 2024; 14(5):2453-2464. PubMed ID: 38859853 [TBL] [Abstract][Full Text] [Related]
4. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG. Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076 [TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985 [TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine Prostate Cancer Drivers SOX2 and BRN2 Confer Differential Responses to Imipridones ONC201, ONC206, and ONC212 in Prostate Cancer Cell Lines. Purcell C; Srinivasan PR; Pinho-Schwermann M; MacDonald WJ; Ding E; El-Deiry WS bioRxiv; 2024 Aug; ():. PubMed ID: 39257809 [TBL] [Abstract][Full Text] [Related]
7. ONC201/TIC10 plus TLY012 anti-cancer effects via apoptosis inhibitor downregulation, stimulation of integrated stress response and death receptor DR5 in gastric adenocarcinoma. Parker CS; Zhou L; Prabhu VV; Lee S; Miner TJ; Ross EA; El-Deiry WS Am J Cancer Res; 2023; 13(12):6290-6312. PubMed ID: 38187068 [TBL] [Abstract][Full Text] [Related]
11. Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC). Liguori NR; Sanchez Sevilla Uruchurtu A; Zhang L; Abbas AE; Lee YS; Zhou L; Azzoli CG; El-Deiry WS Am J Cancer Res; 2022; 12(2):729-743. PubMed ID: 35261798 [TBL] [Abstract][Full Text] [Related]
12. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201. Xin DE; Liao Y; Rao R; Ogurek S; Sengupta S; Xin M; Bayat AE; Seibel WL; Graham RT; Koschmann C; Lu QR Neuro Oncol; 2024 Apr; 26(4):735-748. PubMed ID: 38011799 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells. Bonner ER; Waszak SM; Grotzer MA; Mueller S; Nazarian J Neuro Oncol; 2021 Apr; 23(4):542-556. PubMed ID: 33336683 [TBL] [Abstract][Full Text] [Related]
16. Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma. Meel MH; de Gooijer MC; Metselaar DS; Sewing ACP; Zwaan K; Waranecki P; Breur M; Buil LCM; Lagerweij T; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso Á; Bugiani M; Phoenix TN; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E Clin Cancer Res; 2020 Jul; 26(13):3319-3332. PubMed ID: 32165429 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and Antiproliferative Activity of Novel Imipridone-Ferrocene Hybrids with Triazole and Alkyne Linkers. Czuczi T; Murányi J; Bárány P; Móra I; Borbély A; Csala M; Csámpai A Pharmaceuticals (Basel); 2022 Apr; 15(4):. PubMed ID: 35455465 [TBL] [Abstract][Full Text] [Related]
18. Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Lev A; Lulla AR; Wagner J; Ralff MD; Kiehl JB; Zhou Y; Benes CH; Prabhu VV; Oster W; Astsaturov I; Dicker DT; El-Deiry WS Oncotarget; 2017 Oct; 8(47):81776-81793. PubMed ID: 29137221 [TBL] [Abstract][Full Text] [Related]
19. First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report. Hall MD; Odia Y; Allen JE; Tarapore R; Khatib Z; Niazi TN; Daghistani D; Schalop L; Chi AS; Oster W; Mehta MP J Neurosurg Pediatr; 2019 Jun; 23(6):719-725. PubMed ID: 30952114 [TBL] [Abstract][Full Text] [Related]
20. ONC206 has anti-tumorigenic effects in human ovarian cancer cells and in a transgenic mouse model of high-grade serous ovarian cancer. Tucker K; Yin Y; Staley SA; Zhao Z; Fang Z; Fan Y; Zhang X; Suo H; Sun W; Prabhu VV; Allen JE; Zhou C; Bae-Jump VL Am J Cancer Res; 2022; 12(2):521-536. PubMed ID: 35261784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]